Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (131-140 of 221) with videos related to

Pageof 23
Sort By:
Nature Communications|October 10, 2022
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trialRobert J Motzer, Jean-François Martini, Xinmeng J Mu, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 24, 2019
The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus studyQuentin Denost, Veronique Bousser, Claire Morin-Porchet, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
Radiology|July 26, 2006
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluationThierry de Baère, Jean Palussière, Anne Aupérin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
The Journal of Urology|September 18, 2007
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941Bernard Escudier, Toni K Choueiri, Stéphane Oudard, et al.
Cancer|June 16, 2010
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factorsRobert J Motzer, Bernard Escudier, Stephane Oudard, et al.
Journal of Geriatric Oncology|March 15, 2021
VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patientsLoïc Mourey, Félicien Le Louedec, Alain Ravaud, et al.
Pageof 23

Showing results (131-140 of 221) with videos related to

Sort By:
Pageof 23
Nature Communications|October 10, 2022
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trialRobert J Motzer, Jean-François Martini, Xinmeng J Mu, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 24, 2019
The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus studyQuentin Denost, Veronique Bousser, Claire Morin-Porchet, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
Radiology|July 26, 2006
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluationThierry de Baère, Jean Palussière, Anne Aupérin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
The Journal of Urology|September 18, 2007
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941Bernard Escudier, Toni K Choueiri, Stéphane Oudard, et al.
Cancer|June 16, 2010
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factorsRobert J Motzer, Bernard Escudier, Stephane Oudard, et al.
Journal of Geriatric Oncology|March 15, 2021
VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patientsLoïc Mourey, Félicien Le Louedec, Alain Ravaud, et al.
Pageof 23